Literature DB >> 11033398

Corneal thickness and visual acuity after phacoemulsification with 3 viscoelastic materials.

E A Davis1, R L Lindstrom.   

Abstract

PURPOSE: To determine whether differences exist in visual acuity and corneal thickness after phacoemulsification using various viscoelastic substances.
SETTING: Phillips Eye Institute, Minneapolis, Minnesota, USA.
METHODS: Fifty patients having routine phacoemulsification cataract extraction and intraocular lens implantation by a single surgeon using the same technique were randomly assigned to receive intraoperative administration of 1 of 3 viscoelastic substances: Amvisc Plus(R) (sodium hyaluronate 1.6%), OcuCoat(R) (hydroxypropyl methylcellulose 2%), or Viscoat(R) (chondroitin sulfate 4%-sodium hyaluronate 3%). Visual acuity and corneal thickness on the first postoperative day were compared between groups.
RESULTS: Patients with a best corrected visual acuity (BCVA) of 20/40 or better 1 day postoperatively had significantly thinner corneas (596 microm) than those with a BCVA worse than 20/40 (639 microm). There were no differences in postoperative BCVA or percentage increase in central corneal pachymetry among the 3 viscoelastic groups.
CONCLUSION: Viscoat, Amvisc Plus, and OcuCoat were comparable in their ability to produce clear corneas and good vision after routine phacoemulsification.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11033398     DOI: 10.1016/s0886-3350(00)00436-3

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  2 in total

Review 1.  Impact of Ophthalmic Viscosurgical Devices in Cataract Surgery.

Authors:  Monali S Malvankar-Mehta; Angel Fu; Yasoda Subramanian; Cindy Hutnik
Journal:  J Ophthalmol       Date:  2020-10-20       Impact factor: 1.909

2.  A clinical comparison between DisCoVisc and 2% hydroxypropylmethylcellulose in phacoemulsification: a fellow eye study.

Authors:  Rodrigo F Espíndola; Emerson F S Castro; Marcony R Santhiago; Newton Kara-Junior
Journal:  Clinics (Sao Paulo)       Date:  2012-09       Impact factor: 2.365

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.